Value of caregiver ratings in evaluating the quality of life of patients with cancer. More than 500 community-based oncologists enrolled 2,342 patients with malignancies undergoing cytotoxic ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Data presented here from the ROCKIES phase 3 trial showed use of the investigational ...

WASHINGTON—Roxadustat is superior to epoetin alfa in raising hemoglobin (Hb) levels in incident dialysis patients with anemia, according the results of the phase 3 HIMALAYAS trial of roxadustat ...

April 23, 2007 — Using actual US practice patterns and dosing, epoetin alfa (Epogen; peg-EPO therapy) effectively maintains hemoglobin (Hb) levels in hemodialysis patients, according to a presentation ...

Please provide your email address to receive an email when new articles are posted on . Significantly more patients who received luspatercept vs. epoetin alfa achieved the study’s primary endpoint of ...

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network Patients (N = 301) with ...

CHICAGO -- Patients with transfusion-dependent, low-risk myelodysplastic syndromes (MDS) needed significantly fewer transfusions when treated with luspatercept (Reblozyl) for anemia compared with the ...

Roxadustat met both primary efficacy endpoints of mean hemoglobin (Hb) change from baseline and proportion of patients achieving Hb response in HIMALAYAS WASHINGTON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- ...

In a phase 3 study, the mean hemoglobin change from baseline to average was significantly higher among roxadustat-treated patients compared with epoetin alfa recipients, according to investigators.

Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl. Patients with myelodysplastic syndrome (MDS) ...

Credit: Shutterstock Newly released safety data also show that roxadustat is associated with reduced cardiovascular risks compared with epoetin alfa. WASHINGTON—Roxadustat is superior to epoetin alfa ...